March 13, 2025
“…Government spending eased slightly on a monthly basis though it still far outpaced revenue, according to a Treasury Department statement Wednesday. The deficit totaled just over $307 billion for the month, nearly 2½ times what it was in January and… Continue Reading…
March 6, 2025
“…The trade gap surged 34.0% to an all-time high of $131.4 billion from a revised $98.1 billion in December, the Commerce Department’s Bureau of Economic Analysis (BEA) said on Thursday. The percentage change was the largest since March 2015. Economists… Continue Reading…
September 30, 2024
“Global chip stocks rallied on Thursday after U.S. memory semiconductor maker Micron posted revenue guidance that topped expectations and boosted its share price. Samsung Electronics and SK Hynix both saw their shares rise on Thursday in South Korea. Dutch semiconductor… Continue Reading…
August 14, 2024
“…Here’s how the athletic apparel company did in its fiscal first quarter compared with what Wall Street was anticipating, based on a survey of analysts by LSEG: In the three months ended June 30, Under Armour reported a loss of… Continue Reading…
August 12, 2024
“CervoMed (CRVO) The first Morgan Stanley pick we’ll look at is CervoMed, a clinical-stage medical research firm specializing in neurodegenerative diseases and conditions… Overall, the analyst expects positive clinical results and rates CRVO an Overweight (i.e., Buy). His $35 price… Continue Reading…
August 8, 2024
“Bond traders are piling into bets that the US economy is on the verge of deteriorating so quickly that the Federal Reserve will need to start easing monetary policy aggressively — potentially before their next scheduled meeting — to head… Continue Reading…
July 31, 2024
“…RegenXBio (RGNX) The first Goldman pick we’ll look at is RegenXBio, a gene therapy company specializing in single-dose treatments for severe diseases with few or no existing therapies…. Choi rates RGNX a Buy along with a $38 price target. This… Continue Reading…
June 5, 2024
“…Bloomberg Intelligence says generative AI sales across hardware, software, and services could soar 2,026% to $1.4 trillion by 2032. That puts investors in front of a once-in-a-generation opportunity… Alphabet shares trade at a reasonable valuation Going forward, digital ad spending… Continue Reading…
May 21, 2024
“Sutro Biopharma (STRO)… “We think that luvelta has the potential to treat up to 80% of PROC patients, a significant improvement over the ~30% eligible for AbbVie’s Elahere (approved FolRα ADC)… Overall, the Strong Buy consensus rating on STRO is based… Continue Reading…
Recent Comments